Innovator IBD ETF Leaders ETF Stock Forecast, Price & News

Wall Street analysts have given Innovator IBD ETF Leaders ETF a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Innovator IBD ETF Leaders ETF wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Innovator IBD ETF Leaders ETF's stock was trading at $19.63 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LDRS stock has increased by 44.0% and is now trading at $28.27.
View which stocks have been most impacted by COVID-19.

Innovator IBD ETF Leaders ETF pays an annual dividend of $0.02 per share and currently has a dividend yield of 0.07%.
View Innovator IBD ETF Leaders ETF's dividend history.

Innovator IBD ETF Leaders ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "LDRS."

Innovator IBD ETF Leaders ETF's stock is owned by many different institutional and retail investors. Top institutional shareholders include Susquehanna International Group LLP (10.30%).

LDRS stock was purchased by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP.

Shares of LDRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LDRS stock can currently be purchased for approximately $28.27.

Innovator IBD ETF Leaders ETF has a market capitalization of $8.48 million.